Earnings ·
Innate Pharma reports €19.6M net loss in H1 2026 as revenue rises to €5.7M
IPHAInnate Pharma SA
Innate Pharma SA reported a net loss of €19.6 million for the first half of 2026, compared to a €21.3 million loss in the prior year period. Revenue and other income increased by €0.8 million to €5.7 million, driven primarily by collaboration revenue from Sanofi totaling €3.1 million and research tax credits of €2.5 million. Operating expenses decreased by €5.6 million to €24.7 million, reflecting a reduction in R&D spending due to the completion of lacutamab trials and discontinuation of certain preclinical studies, as well as lower general expenses following workforce reductions. Cash and cash equivalents declined to €6.5 million from €10.9 million at year-end 2025, while net financial assets stood at €21.4 million. The company maintains a collaboration debt of €39.6 million with AstraZeneca for the monalizumab program. Innate Pharma SA is a clinical-stage biotechnology company developing immunotherapies and antibody-drug conjugates for cancer treatment.